Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

LC-MS for Simultaneous Determination of Vancomycin and Teicoplanin in Patient Plasma and its Application to Therapeutic Drug Monitoring

Author(s): Guiyan Yuan, Danni Liu, Fanlong Bu, Yanyan Wang, Benjie Wang and Ruichen Guo*

Volume 15, Issue 1, 2019

Page: [95 - 102] Pages: 8

DOI: 10.2174/1573412914666180801095208

Price: $65

Abstract

Background: Therapeutic drug monitoring is recommended for patients taking vancomycin and teicoplanin to ensure pharmaceutical efficacy and prevent toxicity. Only few studies were reported regarding the simultaneous determination of vancomycin and teicoplanin in human plasma.

Objective: The study aimed at developing and validating a Liquid Chromatography-Mass Spectrometry (LC-MS) method for simultaneous determination and therapeutic drug monitoring of vancomycin and teicoplanin in patients with severe infection.

Method: Plasma was processed by protein precipitation extraction. The analytes were separated on a C18 column by gradient elution with 0.1% formic acid and acetonitrile as mobile phase and measured by electrospray ionization source in positive selective ion monitoring mode at m/z 724.7 (vancomycin), 940.7 (teicoplanin) and 329.0 (bergenin). The plasma samples (104) were obtained from patients who were taking vancomycin or teicoplanin for further analysis.

Results: The calibration curves were linear within the range of 0.25–40 µg/mL for vancomycin, and 0.5-40 µg/mL for teicoplanin. Either inter- or intra-day precision was less than 10.01 %. The extraction recoveries ranged from 89.99 to 94.29% for vancomycin and from 39.83 to 40.16 % for teicoplanin. Vancomycin and teicoplanin in plasma were stable at various storage conditions. The measured mean trough concentrations were 12.313 µg/mL for vancomycin and 8.765 µg/mL for teicoplanin.

Conclusion: This method was successfully applied to therapeutic drug monitoring of vancomycin and teicoplanin in patients. It is with great clinic value for monitoring and predicting the individual response of patients under treatment.

Keywords: Vancomycin, teicoplanin, therapeutic drug monitoring, LC-MS, determination, plasma.

« Previous Next »
Graphical Abstract

[1]
Kaushik, A.; Wagner, C.; Consoer, H.; Chatterjee, A. Strategies for prevention of methicillin resistant staphylococcus aureus (MRSA) infections and decolonization. S. D. Med., 2016, 69(12), 535-539.
[2]
Liu, C.; Bayer, A.; Cosgrove, S.E.; Daum, R.S.; Fridkin, S.K.; Gorwitz, R.J.; Kaplan, S.L.; Karchmer, A.W.; Levine, D.P.; Murray, B.E.; Raybak, M.; Talan, D.A.; Chambers, H.F. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant staphylococcus aureus infections in adults and children: executive summary. Clin. Infect. Dis., 2011, 52(3), 285-292.
[3]
Finch, R.G.; Eliopoulos, G.M. Safety and efficacy of glycopeptide antibiotics. J. Antimicrob. Chemother., 2005, 55(SUPPL_2), ii5- ii13.
[4]
Darley, E.S.; Macgowan, A.P. The use and therapeutic drug monitoring of teicoplanin in the UK. Clin. Microbiol. Infect., 2004, 10(1), 62-69.
[5]
Boulamery, A.; Venisse, N.; Le, G.C. Level of evidence for therapeutic drug monitoring of teicoplatin. Therapie, 2011, 66(1), 45-50.
[6]
Begg, E.J.; Barclay, M.L.; Kirkpatric, C.M. The therapeutic monitoring of antimicrobial agents. Br. J. Clin. Pharmacol., 1999, 47(1), 35-43.
[7]
Ye, Z.K.; Tang, H.L.; Zhai, S.D. Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis. PLoS One, 2013, 8(10), e77169.
[8]
Gould, I.M.; Cauda, R.; Esposito, S.; Gudiot, F.; Mazzei, T.; Garau, J. Management of serious meticillin-resistant Staphylococcus aureus infections: what are the limits? Int. J. Antimicrob. Agents, 2011, 37(3), 202-209.
[9]
Macgowan, A.; Lovering, A.; White, L.; Reeves, D.; Collyns, T.A.; Oppenheim, B.A.; Wysocki, M.; Thomas, F.; Wolff, M.; Hoog, M.D.; Mouton, J.W.; Anker, J.N.; Duffull, S.B.; Begg, E.; Saunders, N. Why monitor peak vancomycin concentrations? Lancet, 2016, 345(8950), 646-647.
[10]
Tobin, C.M.; Lovering, A.M.; Sweeney, E.; Macgowan, A.P. Analyses of teicoplanin concentrations from 1994 to 2006 from a UK assay service. J. Antimicrob. Chemother., 2010, 65(10), 2155-2157.
[11]
Rybak, M.J.; Bailey, E.M.; Reddy, V.N. Clinical evaluation of teicoplanin fluorescence polarization immunoassay. Antimicrob. Agents Chemother., 1991, 35(8), 1586-1590.
[12]
Mccann, S.J.; White, L.O.; Keevil, B. Assay of teicoplanin serum: comparison of high-performance liquid chromatography and fluorescence polarization immunoassay. J. Antimicrob. Chemother., 2002, 50(1), 107-110.
[13]
Mochizuki, N.; Ohno, K.; Shimamura, T.; Furukawa, H.; Todo, S.; Kishino, S. Quantitative determination of individual teicoplanin in components in human plasma and cerebrospinal fluid by high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2017, 847(2), 78-81.
[14]
Abushandi, K.H. Determination of vancomycin in human plasma using high- performance liquid chromatography with fluorescence detection. Anal. Bioanal. Chem., 2009, 395(2), 527-532.
[15]
Luksa, J.; Marusic, A. Rapid high-performance liquid chromatographic determination of vancomycin in human plasma. J. Chromatogr. B Biomed. Appl., 1995, 667(2), 277-281.
[16]
Zhang, T.; Watson, D.G.; Azike, C.; Tettey, J.N.A.; Stearns, A.T.; Binning, A.R.; Payne, C.J. Determination of vancomycin in serum by liquid chromatography-high resolution full scan mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 857(2), 352-356.
[17]
Fung, F.H.; Tang, J.C.; Hopkins, J.P.; Dutton, J.; Bailey, L.; Davison, A. Measurement of teicoplanin by liquid chromatography-tandem mass spectrometry: development of a novel method. Ann. Clin. Biochem., 2012, 49(Pt5), 475-481.
[18]
Smith, D.S.; Eremin, S.A. Fluorescence polarization immunoassays and related methods for simple, high-throughput screening of small molecules. Anal. Bioanal. Chem., 2008, 391(5), 1499-1507.
[19]
Taylor, P.J.; Tai, C.H.; Franklin, M.E.; Pillans, P.I. The current role of liquid chromatography-tandem mass spectrometry in therapeutic drug monitoring of immunosuppressant and antiretroviral drugs. Clin. Biochem., 2011, 44(1), 14-20.
[20]
Ye, Z.K.; Chen, Y.L.; Chen, K.; Zhang, X.L.; Du, G.H.; He, B.; Li, D.K.; Liu, Y.N.; Yang, K.H.; Zhang, Y.Y.; Zhai, S.D. Therapeutic drug monitoring of vancomycin: a guideline of the division of therapeutic drug monitoring, Chinese pharmacological society. J. Antimicrob. Chemother., 2016, 71(11), 3020-3025.
[21]
Ye, Z.K.; Li, C.; Zhai, S.D. Guidelines for therapeutic drug monitoring of vancomycin: A systematic review. PLoS One, 2014, 9(6), e99044.
[22]
Kim, S.W. Is therapeutic drug monitoring of teicoplanin useful? Infect. Chemother., 2014, 46(1), 64-65.
[23]
Oda, K.; Kasada, T.; Yoshikawa, M.; Tanoue, M.; Yamashita, T.; Takeshita, Y. Therapeutic drug monitoring based on early measurements of serum teicoplanin levels in Japanese patients. Ther. Drug Monit., 2014, 36(3), 401-405.

Rights & Permissions Print Cite
Article Metrics
27
3
© 2024 Bentham Science Publishers | Privacy Policy